Tremfya and Icotide are touted as key growth drivers in J&J’s strongly performing innovative medicines business.

Johnson & Johnson JNJ announced that the European Commission (EC) has approved an expanded use of its blockbuster psoriasis drug, Tremfya, in children. Tremfya is now approved to treat pediatric and ...

Johnson & Johnson JNJ announced that the European Commission (EC) has approved an expanded use of its blockbuster psoriasis drug, Tremfya, in children. Tremfya is now approved to treat pediatric and ...

The psoriasis market is experiencing steady growth, driven by rising disease prevalence, improved diagnosis rates, and ...

Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...

The psoriasis market is experiencing steady growth, driven by rising disease prevalence, improved diagnosis rates, and greater patient access to advanced therapies. The shift from conventional ...

Xoma argued Janssen breached the contract Xoma had with the third-party pharmaceutical company, as well as the contract the company and Janssen had, by failing to obtain a commercial license from Xoma ...

The first two days of the J.P. Morgan Healthcare Conference are in the books, and attendees are now pushing through to finish ...

Bimekizumab exhibited superior drug survival rates among patients with psoriasis who have previously stopped responding to at ...

Alumis Inc. surged on Phase 3 psoriasis data for envudeucitinib. Click for this look at ALMS stock and why I am bullish on ...

Investing in dividend-paying stocks is one of numerous approaches that can help you maximize your portfolio growth, and ...